Dr Timothy Hatlen, a Lundquist Institute Investigator, shares positive news about treatment of Hepatits C Virus Infections
Phase 3 trial for the treatment of chronic hepatitis C virus (HCV) infection conducted in North America met its Primary Endpoint of Statistical Non-inferiority according to a press release by the sponsor, Atea Pharmaceuticals, Inc. ...








